M
Michele Caraglia
Researcher at Seconda Università degli Studi di Napoli
Publications - 562
Citations - 24508
Michele Caraglia is an academic researcher from Seconda Università degli Studi di Napoli. The author has contributed to research in topics: Cancer & Cancer cell. The author has an hindex of 67, co-authored 525 publications receiving 20615 citations. Previous affiliations of Michele Caraglia include Temple University & Magna Græcia University.
Papers
More filters
Journal ArticleDOI
Phase II studies of anticancer chemotherapy: indirect evidence of poor quality
TL;DR: It was found that phase II studies were more likely to be published in low IF journals than phase III studies (P <0.0001), and evidence in literature indicates that this is more likely related to the quality of these studies than to editorial policy.
Journal ArticleDOI
Initial tumour burden and hidden oligometastatic disease in phase 3 clinical trials.
TL;DR: In this paper , the selection of patients for inclusion in phase 3 trials relies on prespecified clinical and methodological rules (eg, clinical characteristics, randomisation procedure, and stratification factors) to keep the risk of biases affecting the strength and standardisation of results as low as possible.
Book ChapterDOI
miRNA as Prognostic and Therapeutic Targets in Tumor of Male Urogenital Tract
TL;DR: The most important advantage in miRNAs is the multiple targeting of different intracellular molecules that results in the amplification of the biological effect induced by miRNA.
Journal ArticleDOI
Bevacizumab-Induced Tumor Vasculature Normalization and Sequential Chemotherapy in Colorectal Cancer: An Interesting and Still Open Question.
TL;DR: In this paper, a randomized phase III study (OBELICS) comparing the sequential administration of bevacizumab before standard oxaliplatin-based chemotherapy versus a traditional concomitant regimen in metastatic colorectal cancer (CRC) was conducted.
Proceedings ArticleDOI
Differential transcriptional response to cisplatinum in BRCA1-defectiveversusBRCA1-reconstituted breast cancer cells by microarrays.
M T Di Martino,Monica Ventura,Pietro Hiram Guzzi,Antonella Pietragalla,Paola Neri,Alessandra Bulotta,Teresa Calimeri,Vito Barbieri,Michele Caraglia,Pierangelo Veltri,Mario Cannataro,Pierfrancesco Tassone,Pierosandro Tagliaferri +12 more
TL;DR: The results suggest that reconstituted expression of BRCA1 induces resistance to CDDP in vitro and in vivo but produces a different transcriptional response to drug exposure, which reinforces the concept that BRCa1 offers a molecular marker for individualized therapeutical options in breast cancer patients.